Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RARE$16.14-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Treasury · Deferred Compensation · TotalStockholders' | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Stock | Obligation | Equity | |
| Balance as of December 31, 2020 | 66,818,520 | $67 | $2,773,195 | $689 | $(1,619,576) | $— | $— | $1,154,375 |
| Issuance of common stock in connection with at-the-market offering, net of issuance costs | 1,050,372 | 1 | 78,942 | — | — | — | — | 78,943 |
| Stock-based compensation | — | — | 105,260 | — | — | — | — | 105,260 |
| Issuance of common stock under equity plan awards, net of tax | 1,476,106 | 1 | 40,100 | — | — | — | — | 40,101 |
| Other comprehensive loss | — | — | — | (2,093) | — | — | — | (2,093) |
| Net loss | — | — | — | — | (454,025) | — | — | (454,025) |
| Balance as of December 31, 2021 | 69,344,998 | $69 | $2,997,497 | $(1,404) | $(2,073,601) | $— | $— | $922,561 |
| Stock-based compensation | — | — | 131,710 | — | — | — | — | 131,710 |
| Issuance of common stock under equity plan awards, net of tax | 852,299 | 1 | 10,812 | — | — | — | — | 10,813 |
| Other comprehensive loss | — | — | — | (5,169) | — | — | — | (5,169) |
| Net loss | — | — | — | — | (707,421) | — | — | (707,421) |
| Balance as of December 31, 2022 | 70,197,297 | $70 | $3,140,019 | $(6,573) | $(2,781,022) | $— | $— | $352,494 |
| Issuance of common stock and pre-funded warrants in connection with underwritten public offering, net of issuance costs | 9,833,334 | 10 | 326,446 | — | — | — | — | 326,456 |
| Issuance of common stock in connection with at-the-market offering, net of issuance costs | 1,175,584 | 1 | 53,298 | — | — | — | — | 53,299 |
| Stock-based compensation | — | — | 134,169 | — | — | — | — | 134,169 |
| Issuance of common stock under equity plan awards, net of tax | 1,109,375 | 1 | 8,414 | — | — | — | — | 8,415 |
| Deferred compensation | — | — | — | — | — | (432) | 432 | — |
| Other comprehensive income | — | — | — | 7,220 | — | — | — | 7,220 |
| Net loss | — | — | — | — | (606,639) | — | — | (606,639) |
| Balance as of December 31, 2023 | 82,315,590 | $82 | $3,662,346 | $647 | $(3,387,661) | $(432) | $432 | $275,414 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.